OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited is set to present its promising trial results for OK-101, a treatment for dry eye disease, at the International Tear Film & Ocular Surface Society Conference in Venice. The company is also advancing its Phase 2 trial for treating Neuropathic Corneal Pain, a market with no current FDA-approved therapies. These developments highlight OKYO’s commitment to addressing challenging ocular conditions and expanding its presence in the multi-billion-dollar eye care market.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
